Clinical Trial Update: Phase 1 TheraSphere + Everolimus With Neuroendocrine Tumors (NETs) + Liver Only or Liver Dominant Disease [Phase 1]

View source ↗

Summary

A Phase 1 trial of TheraSphere in combination with Everolimus for neuroendocrine tumors with liver-dominant disease has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Liver Cancer
• Neuroendocrine Tumor

Drugs mentioned

• Everolimus (everolimus)
• TheraSphere (yttrium-90 glass microspheres)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Liver Cancer | Phase 1 | Status: WITHDRAWN